OptiBiotix Health PLC Scientific and Commercial Update (3520Q)
November 29 2016 - 1:00AM
UK Regulatory
TIDMOPTI
RNS Number : 3520Q
OptiBiotix Health PLC
29 November 2016
OptiBiotix Health plc
("OptiBiotix" or the "Company")
Scientific and Commercial Update
OptiBiotix Health plc (AIM: OPTI), a life sciences business
developing compounds to tackle obesity, high cholesterol, diabetes
and skin care, provides the following scientific and commercial
update.
Scientific Update
OptiBiotix has made significant progress in its scientific
programmes to develop compounds which modify the human microbiome
to prevent, manage and treat disease. The Company believes these
developments have the potential to rapidly accelerate the Company's
growth. Recent developments include: -
-- OptiBiotix's ability to manipulate both the microbiome's
composition and its function. This creates the potential for:-
ü Designer ingredients or supplements which can modify an
individual's current microbiome to improve health.
ü The potential for precision microbiome medicine. This is an
area of growing scientific and commercial interest with growing
evidence that the microbiome plays an important role in how the
body metabolises pharmaceutical products, influencing their
effectiveness and the potential for adverse reactions.
-- OptiBiotix has demonstrated the ability of its novel
oligosaccharides (carbohydrates that consist of a small number of
sugars) to reduce cholesterol in human gut models by >20%. These
sugars are heat resistant and stable during processing making them
suitable as ingredients in a wide range of products. This finding
extends the existing product opportunity offered by OptiBiotix's
LP-LDL cholesterol reducing strain from supplements to ingredients,
greatly increasing the market opportunity.
The results of these studies have been submitted for publication
and presentation in mainstream scientific journals and conferences
throughout 2017.
Commercial Update
OptiBiotix reports that it has reached late stage commercial
discussions with six commercial partners across its technology and
product platforms. A number of these discussions have been ongoing
for many months and have involved extensive due diligence of
OptiBiotix's science, intellectual property, and the partners
assessment of the scale of the market opportunity across
international markets. These discussions include a number of
leading industry corporate players who provide product development,
manufacturing, distribution, and/or routes to global markets.
Whilst OptiBiotix cannot guarantee that all discussions will
lead to commercial deals it wants to update shareholders on the
ongoing commercial progress being made across all of its products
and platforms.
Stephen O'Hara, CEO of OptiBiotix, commented: "The Company
believes it is making strong scientific progress across all its
technology and product platforms. These research findings add to
the growing scientific evidence base of how OptiBiotix's technology
influences the microbiome to prevent, manage, and treat disease.
This helps convert existing commercial interest into commercial
deals and opens up opportunities in new markets. The overall aim
being to develop multiple revenue streams from both consumer and
pharmaceutical products across all its technology platforms."
This announcement contains inside information for the purposes
of Article 7 of EU Regulation 596/2014
For further information, please contact:
OptiBiotix Health plc www.optibiotix.com
Stephen O'Hara, Chief Executive Contact via
Walbrook below
Cairn Financial Advisers LLP Tel: 020 7213
0880
Liam Murray
finnCap Broker Tel: 020 7220
0500
Adrian Hargrave / Scott Mathieson
/ Kate Bannatyne (Corporate Finance)
Tony Quirke (Corporate Broking)
Walbrook PR Ltd Tel: 020 7933 8780 or optibiotix@walbrookpr.com
Anna Dunphy Mob: 07876 741
001
About OptiBiotix - www.optibiotix.com
OptiBiotix was formed in March 2012 to develop compounds which
modify the human microbiome - the collective genome of the microbes
in the body - to prevent and manage human disease.
The aim of OptiBiotix is to discover and develop microbial
strains, compounds and formulations, which modulate the human
microbiome and can be used as food ingredients and supplements or
active compounds for the prevention and management of human
metabolic diseases, examples of which include obesity, cholesterol
and lipid distribution and diabetes.
OptiBiotix has established a pipeline of microbiome modulators
that can impact on lipid and cholesterol management, energy harvest
and appetite suppression. The development pipeline is fuelled by
its proprietary OptiScreen(R) and OptiBiotic(R) platform
technologies designed to identify metabolic pathways and compounds
that impact on human physiology and bring potential health
benefits. These platforms are applicable across a wider range of
other human diseases.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCEAXFPAFAKFFF
(END) Dow Jones Newswires
November 29, 2016 02:00 ET (07:00 GMT)
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Apr 2023 to Apr 2024